Pezzicoli G - Search Results

1

[The Treatment of Metastatic Renal Cell Carcinoma: An Update].

Pezzicoli G, Ganini C, Re Sartò GV, Pirovano M, Cosmai L, Porta C. Pezzicoli G, et al. G Ital Nefrol. 2023 Oct 3;40(Suppl 81):2023-S81. G Ital Nefrol. 2023. PMID: 38007832 Review. Italian.

2

IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma.

Rizzo M, Varnier L, Pezzicoli G, Pirovano M, Cosmai L, Porta C. Rizzo M, et al. Among authors: pezzicoli g. Front Oncol. 2022 Aug 19;12:990568. doi: 10.3389/fonc.2022.990568. eCollection 2022. Front Oncol. 2022. PMID: 36059687 Free PMC article. Review.

3

Playing the Devil's Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? - ie Strategies to Revert Resistance to mTOR Inhibitors.

Pezzicoli G, Filoni E, Gernone A, Cosmai L, Rizzo M, Porta C. Pezzicoli G, et al. Cancer Manag Res. 2021 Oct 4;13:7623-7636. doi: 10.2147/CMAR.S267220. eCollection 2021. Cancer Manag Res. 2021. PMID: 34675658 Free PMC article. Review.

4

MiT translocation renal cell carcinoma: A review of the literature from molecular characterization to clinical management.

Rizzo M, Pezzicoli G, Santoni M, Caliò A, Martignoni G, Porta C. Rizzo M, et al. Among authors: pezzicoli g. Biochim Biophys Acta Rev Cancer. 2022 Nov;1877(6):188823. doi: 10.1016/j.bbcan.2022.188823. Epub 2022 Oct 12. Biochim Biophys Acta Rev Cancer. 2022. PMID: 36240899 Review.

5

Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification.

Rizzo M, Caliò A, Brunelli M, Pezzicoli G, Ganini C, Martignoni G, Camillo P. Rizzo M, et al. Among authors: pezzicoli g. Cancer Treat Rev. 2023 May;116:102558. doi: 10.1016/j.ctrv.2023.102558. Epub 2023 Apr 9. Cancer Treat Rev. 2023. PMID: 37060647 Review.

6

Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma.

Marconcini R, Pezzicoli G, Stucci LS, Sergi MC, Lospalluti L, Porta C, Tucci M. Marconcini R, et al. Among authors: pezzicoli g. Hum Vaccin Immunother. 2022 May 31;18(3):1980315. doi: 10.1080/21645515.2021.1980315. Epub 2021 Oct 6. Hum Vaccin Immunother. 2022. PMID: 34613889 Free PMC article. Review.

7

Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer.

Guarini C, Grassi T, Pezzicoli G, Porta C. Guarini C, et al. Among authors: pezzicoli g. Int J Mol Sci. 2021 Jun 24;22(13):6813. doi: 10.3390/ijms22136813. Int J Mol Sci. 2021. PMID: 34202896 Free PMC article. Review.

8

A Glimpse in the Future of Malignant Mesothelioma Treatment.

Pezzicoli G, Rizzo M, Perrone M, Minei S, Mutti L, Porta C. Pezzicoli G, et al. Front Pharmacol. 2021 Dec 15;12:809337. doi: 10.3389/fphar.2021.809337. eCollection 2021. Front Pharmacol. 2021. PMID: 34975505 Free PMC article. Review.

9

Biliary tract cancers: moving from the present standards of care towards the use of immune checkpoint inhibitors.

Pezzicoli G, Triggiano G, Sergi MC, Mannavola F, Porta C, Tucci M. Pezzicoli G, et al. Am J Transl Res. 2021 Aug 15;13(8):8598-8610. eCollection 2021. Am J Transl Res. 2021. PMID: 34539982 Free PMC article. Review.

10

Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications.

Lauricella E, Mandriani B, Cavallo F, Pezzicoli G, Chaoul N, Porta C, Cives M. Lauricella E, et al. Among authors: pezzicoli g. Front Oncol. 2022 Aug 17;12:957068. doi: 10.3389/fonc.2022.957068. eCollection 2022. Front Oncol. 2022. PMID: 36059642 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Search Page

Filters